Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medical Developments International (ASX:MVP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medical Developments International EBITDA Margin % Related Terms
Medical Developments International EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medical Developments International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International (ASX:MVP) has a EBITDA Margin % of 9.92% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medical Developments International and its competitors. This is 21% above median its historical median of 8.23. According to the industry distribution chart, Medical Developments International ranks #598 out of 958 companies in the Drug Manufacturers industry, placing it in the top 62.4%.
Is Medical Developments International's EBITDA Margin % too high?
Medical Developments International's current EBITDA Margin % of 9.92% is 21% above median its 10-year median of 8.23. The Drug Manufacturers industry median EBITDA Margin % is 12.45. Medical Developments International's value of 9.92% is 20.3% below this industry median. Based on the distribution chart, Medical Developments International ranks #598 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Medical Developments International has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #598 out of 958 companies for EBITDA Margin %. This places Medical Developments International in the lower half of its industry. The industry median EBITDA Margin % is 12.45. Medical Developments International's value of 9.92% is 20.3% below this benchmark. While the company's 10-year median is 8.23 vs. the industry median of 12.45, Medical Developments International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current EBITDA Margin % of 9.92% is 20.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current EBITDA Margin % is 9.92%, which is 21% above median its own 10-year median of 8.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.52, compared to a current price of A$0.46 — trading 12.5% below its estimated fair value. The current EBITDA Margin % is 9.92%, which is 21% above median its 10-year median of 8.23 and 20.3% below the Drug Manufacturers industry median of 12.45. Medical Developments International's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current EBITDA Margin % is 9.92% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (ASX:MVP) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of A$0.46 is trading 12.5% below its estimated GF Value™ of A$0.52.
GuruFocus considers Medical Developments International to be Modestly Undervalued.
Key valuation signals for ASX:MVP:
EBITDA Margin %: 9.92% (21% above median its 10-year median of 8.23)
GF Value™: A$0.52 vs. price of A$0.46 (12.5% below fair value)
Industry Position: 20.3% below the Drug Manufacturers median (#598 of 958)
No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
58GF Score
Get the complete analysis for ASX:MVP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVP has been successfully added to your 
